Urinary exosomal mRNA as a biomarker for the diagnosis of bladder cancer
Xinying Wang,Dianbin Song,Baoxing Zhu,Yang Jin,Caisen Cai,Zhiyong Wang
DOI: https://doi.org/10.1097/cad.0000000000001571
2024-03-09
Anti-Cancer Drugs
Abstract:Bladder cancer is one of the most common malignant tumors of the urinary system. Bladder cancer is a common malignancy in women and the fourth most common cancer in men, accounting for 7% of all newly diagnosed cancers. As the eighth leading cause of cancer death, bladder cancer accounts for 4% of all cancer deaths in American men [ 1 ]. In China, the incidence and mortality of bladder cancer are also increasing year by year [ 2 ]. Bladder tumors can manifest as gross or microscopic hematuria. Based on the degree of hematuria and the risk of malignant tumors, evaluations are performed using cystoscopy and upper urinary tract imaging. About 70% of bladder cancers are nonmuscle-invasive bladder cancer. The main treatment for nonmuscle-invasive bladder cancer is transurethral resection of bladder tumor and intravesical therapy, but it has a high recurrence rate [ 3 ]. About 20–30% of bladder cancers are muscle-invasive bladder cancer. More aggressive treatments are necessary, including radical cystectomy, urinary diversion surgery or trimodal therapy, including maximal transurethral resection of bladder tumor, radiosensitizing chemotherapy and radiotherapy to reduce the risks of metastasis and disease-specific mortality. Bladder cancer surgery is highly traumatic, with many postoperative complications, easy recurrence and poor prognosis [ 4 ]. Therefore, early detection, diagnosis and treatment are crucial for the prognosis of bladder cancer patients. In recent years, diagnosis of bladder cancer is usually based on cytology, ultrasound (US) and cystoscopy, all having certain limitations. Although cytological assessment and US are noninvasive, inexpensive and easy to implement, they have low sensitivity [ 5 ]. Cystoscopy is currently the gold standard for bladder cancer diagnosis, but it has some invasiveness, causing pain and discomfort to patients, and risks of urinary tract infections [ 6 ]. Due to the limited success rate and complications of such invasive biopsies, there is a growing need to explore a noninvasive, reliable biomarker for bladder cancer. The detection of biomarkers in urine by liquid biopsy represents a promising new noninvasive approach to overcome these limitations and supplement current clinical practice. However, current biomarkers lack sufficient clinical value. Therefore, it is clinically significant to identify new biomarkers for the early diagnosis of bladder cancer [ 7 ].
oncology,pharmacology & pharmacy